Institutional investors purchased a net $2.8 million shares of MYGN during the quarter ended March 2017 and now own 124.83% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 3.9 Million shares of Myriad Genetics Inc
D. E. SHAW & CO. LP Bought 1.4 Million shares of Myriad Genetics Inc
DIMENSIONAL FUND ADVISORS LP Bought 988.0 Thousand shares of Myriad Genetics Inc